HOpe for contrast-induced acute kidney injury  by Curtis, L.M. & Agarwal, A.
Kidney International (2007) 72       907
commentar yhttp://www.kidney-international.org
© 2007 International Society of Nephrology
HOpe for contrast-induced acute 
kidney injury
LM Curtis1 and A Agarwal1
Contrast-induced nephropathy (CIN) is a common cause of acute 
kidney injury in hospitalized patients. The mechanisms involved in 
the pathogenesis of CIN are incompletely understood. Goodman et 
al. have demonstrated for the first time that heme oxygenase-1,  
a 32-kilodalton protein with antioxidant, antiapoptotic, anti-
inflammatory effects, is induced in the kidney and, importantly, 
provides a beneficial effect in CIN.
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Contrast-induced nephropathy (CIN) is 
the third most common cause of acute 
kidney injury,1 occurring in up to 5% of 
hospitalized patients who exhibit normal 
renal function prior to introduction of 
contrast, and in up to 50% of those with 
preexisting renal dysfunction.2 As many 
as a third of patients diagnosed with 
CIN have some permanent renal insuf-
ficiency. A considerable proportion of 
patients diagnosed clinically with CIN 
may also have atheroembolic renal dis-
ease. Patients with prior chronic kidney 
disease are particularly susceptible, dem-
onstrating increased short- and long-term 
mortality.3,4 Importantly, death from CIN 
per se is uncommon; more commonly, 
nonrenal complications such as sepsis, 
bleeding, delirium, and respiratory fail-
ure predominate.5 Notably, the presence 
of increased nonrenal complications leads 
to substantial economic impact as a result 
of increased health-care resource utiliza-
tion.6 Clearly, prevention and therapeutic 
interventions for CIN are important areas 
for investigation.
Adequate volume expansion, choice of 
contrast agent, and dosing schedule are 
known to have a beneﬁcial eﬀect against 
CIN, although complete protection is 
not afforded by these considerations 
(reviewed by Stacul et al.7). Interestingly, 
the use of sodium bicarbonate rather than 
sodium chloride was shown to provide 
greater protective eﬀects.8 Several phar-
macological agents have been tested with 
varying results and require further evalu-
ation. Among the pharmacological agents 
tested, pretreatment of patients with anti-
oxidants, such as N-acetylcysteine9,10 and 
ascorbic acid11 as well as dopamine and 
fenoldopam (a selective dopamine-1 ago-
nist),12,13 has been evaluated in clinical 
trials of CIN, with conﬂicting results.14,15 
The CIN Consensus Working Panel has 
therefore recently published the follow-
ing guidelines on preventive strategies to 
reduce risk for CIN:7 (1) that adequate 
intravenous volume expansion with isot-
onic crystalloid (1.0–1.5 ml/kg per hour) 
should be achieved for 3–12 hours before 
the procedure and continued for 6–24 
hours thereafter, and (2) that no adjunc-
tive medical or mechanical treatment is 
beneﬁcial to date.
The exact pathogenesis of CIN is not 
completely understood. Multiple factors, 
including renal vasoconstriction, direct 
renal tubular toxicity, and increased oxi-
dative stress, contribute to the histologi-
cal changes of proximal tubular damage 
that manifest in CIN.16 Elegant work in 
the early 1990s in the ﬁeld of oxidative 
stress had highlighted the importance of 
a 32-kilodalton protein, heme oxygen-
ase-1 (HO-1), that was robustly induced 
when cells were challenged with a vari-
ety of oxidant stressors in vitro17 and 
in rhabdomyolysis-induced acute kid-
ney injury in vivo.18 More importantly, 
prior induction of HO-1 was protective, 
whereas blockade of HO enzyme activity 
resulted in signiﬁcant worsening of renal 
injury, providing the ﬁrst demonstration 
for the functional signiﬁcance of HO-1 in 
tissue injury.18 These ﬁndings have since 
been extended to models of acute kidney 
injury secondary to ischemia–reperfusion 
and nephrotoxins (for example, cisplatin) 
(reviewed by Nath19), and now to CIN.20
Goodman and colleagues20 (this issue) 
have now examined the role of HO-1 in a 
model of CIN and show for the ﬁrst time 
that acute kidney injury following contrast 
exposure is attenuated by HO-1 induc-
tion. Because it is diﬃcult to induce CIN 
with contrast medium alone in rodents 
with normal kidney function, the authors 
used a rat model of CIN in salt-depleted, 
indomethacin-treated, and uninephrecto-
mized male Sabra rats given the contrast 
agent, sodium iothalamate (60% Angio-
Conray). HO-1 (inducible isoform) was 
markedly upregulated in the renal cortex 
after CIN in this model, but levels of HO-
2 (constitutive isoform) were not altered. 
Inhibition of HO enzyme activity with 
tin mesoporphyrin caused worsening of 
renal function associated with increased 
superoxide levels after CIN, whereas HO-
1 induction with cobalt protoporphyrin 
reversed these eﬀects. The authors also 
demonstrate that HO-1 induction was 
associated with restoration of endothe-
lial and inducible nitric oxide synthase 
levels and an increase in the antiapop-
totic proteins Bcl-2 (in the medulla) 
and Bcl-xl (in both cortex and medulla). 
Inhibition of HO activity increased Bax 
to levels higher than those observed with 
CIN alone. In addition, HO-1 induction 
attenuated the increase in the proapop-
totic proteins caspase-3 and caspase-9. 
These results demonstrate an important 
mechanistic role for HO-1 in CIN. The 
authors also observed an inverse rela-
tionship between HO-1 induction and 
proapoptotic proteins in the cortex and 
medulla, a particularly noteworthy ﬁnd-
ing. The lack of HO-1 induction in the 
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medulla after CIN was associated with 
increased levels of caspases and Bax only 
in the medulla and not in the cortex, the 
location where HO-1 was induced in 
response to CIN alone. In contrast, in the 
cobalt protoporphyrin-treated animals, 
induction of HO-1 in the renal medulla 
resulted in protective eﬀects due to a shift 
from a proapoptotic to an antiapoptotic 
proﬁle. These observations further high-
light the protective role of endogenous 
HO-1 in acute kidney injury.
A schematic summarizing the protec-
tive role of HO-1 in CIN is depicted in 
Figure 1. In high-risk settings, contrast 
exposure can lead to renal proximal 
tubular damage via ischemia secondary 
to vasoconstriction, increased oxidative 
stress, or direct tubular-cell toxicity lead-
ing to acute kidney injury. The heightened 
state of oxidative stress, possibly from 
increased levels of heme released from 
destabilized heme proteins21 or other 
stimuli, results in the induction of HO-1 
in renal tubules as an adaptive and protec-
tive response. HO-1 breaks down heme to 
carbon monoxide (CO), biliverdin, and 
iron. Biliverdin is converted to bilirubin 
by biliverdin reductase. The released iron 
is scavenged by ferritin. HO-1 is known to 
mediate potent antioxidant, anti-inﬂam-
matory, antiapoptotic, and vasodilatory 
eﬀects through one or more of its prod-
ucts.19 It is important to note that the 
products of HO enzyme activity, biliver-
din/bilirubin22 and CO (administered as 
a gas or a CO-releasing molecule),23,24 
are protective in other animal models of 
acute kidney injury. Furthermore, recent 
studies have shown that several therapeu-
tic interventions in acute kidney injury 
mediate their protective eﬀects through 
the induction of HO-1. For example, 
neutrophil gelatinase-associated lipocalin 
(NGAL)–siderophore–iron, a protein that 
is highly induced after ischemic kidney 
injury, when administered exogenously 
exerts remarkable protection in acute 
kidney injury through induction of HO-
1.25 Similarly, α-melanocyte-stimulating 
hormone, erythropoietin, interleukin-10, 
and statins that are protective in animal 
models of acute kidney injury potently 
induce HO-1 in vitro and/or in vivo.26–29 
Several of these interventions have been 
shown to be protective in CIN as well 
(reviewed by Stacul et al.7).
Further exploration of the role of HO-1 
in CIN is warranted, as several questions 
remain to be answered. The use of genetic 
modulation of HO-1 with transgenic 
knockout and overexpressing animal 
models in CIN would provide valu-
able information and would obviate the 
potential limitations of pharmacological 
manipulation of the HO-1 pathway. The 
precise location, the proximate stimulus 
for HO-1 induction in the kidney, and the 
eﬀects of site-speciﬁc HO-1 ablation or 
overexpression in CIN would be of inter-
est. Identiﬁcation of the protective eﬀects 
of the product or products of the HO-1 
reaction (CO, biliverdin, bilirubin) in CIN 
would be a logical extension for this work. 
Indeed, the HO-1 pathway may provide 
HOpe for preventing or reducing the risk 
of contrast-induced acute kidney injury.
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Vitamin D as a novel 
nontraditional risk factor for 
mortality in hemodialysis 
patients: The need for 
randomized trials
Z Al-Aly1–3
Vitamin D has been used in the context of secondary 
hyperparathyroidism in patients with end-stage renal disease. A wave 
of recent studies suggests that vitamin D treatment may be associated 
with decreased mortality risk in these patients. The article by Wolf et al. 
further supports these studies by identifying vitamin D deficiency as a 
risk factor for early mortality in incident hemodialysis patients.
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Vitamin D has been used in the context 
of secondary hyperparathyroidism in 
patients with chronic kidney disease. 
Recently a body of evidence started to 
emerge pointing to the high prevalence 
of vitamin D deﬁciency and suggesting 
that, beyond its effect on parathyroid 
hormone (PTH) and divalent ion homeo-
stasis, vitamin D replacement may aﬀect 
survival in patients with end-stage renal 
disease (ESRD). However, the effect 
of vitamin D treatment on survival in 
patients with ESRD has been examined 
only in retrospective studies. A historical 
cohort study of 51,037 patients on hemo-
dialysis suggested that patients treated 
with activated injectable vitamin D had a 
2-year survival beneﬁt of 20% compared 
with patients who did not receive any 
activated injectable vitamin D treatment 
(hazard ratio 0.80, 95% conﬁdence inter-
val 0.76–0.83, P < 0.01).1 These results 
were echoed in another cohort study, 
which examined mortality associated 
with vitamin D use in 14,967 incident 
hemodialysis patients in a not-for-proﬁt 
dialysis network. The results revealed that 
almost half of the patients (46.9%) did not 
receive any injectable vitamin D and that 
those patients (6,855) had an increased 
mortality risk with a hazard ratio of 1.20 
(1.10–1.32, P < 0.05).2 Another study of 
1,007 incident hemodialysis and perito-
neal dialysis patients showed 26% lower 
mortality in patients who received calci-
triol compared with those who did not 
receive any vitamin D (hazard ratio 0.74 
(0.56–1.00), P < 0.05).3 In a Japanese 
study of 242 hemodialysis patients, there 
was no diﬀerence in the risk of death from 
non-cardiovascular disease in patients 
who received α-calcidol and those who 
did not. The use of α-calcidol, however, 
signiﬁcantly lowered the risk of death due 
to cardiovascular disease (hazard ratio 
0.287 (0.13–0.65), P = 0.003).4
These results are not universal and 
depend to a signiﬁcant degree on the 
statistical model used and the covari-
ates included in the regression analysis. 
